HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS closes Longs deal, reports OTC growth

This article was originally published in The Tan Sheet

Executive Summary

CVS/Caremark announces Oct. 30 the finalization of its acquisition of Longs Drug Stores Corp., which has 521 locations in markets mostly without a CVS presence, including Hawaii and central and northern California (1"The Tan Sheet" Aug. 18, 2008, p. 19). CVS/Caremark President and CEO Tom Ryan says the deal "accelerates our expansion into key growth markets." The Woonsocket, R.I.-based firm also reports third quarter retail sales of $11.5 billion, a 5.3 percent jump. Ryan says the cough/cold business "is up double-digit year-to-date" and the OTC health care category and private-label sales are up. He attributes the increases to "economic step therapy," in which consumers self-medicate before seeking costlier health care

You may also be interested in...



CVS Stretches California Footprint, Reaches Hawaii With Longs Buy

CVS/Caremark is gaining a retail pharmacy presence in major new markets in California and other western states through its acquisition of Longs

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel